(Q36744800)

16 August 2017

Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro (English)

1 reference

16 August 2017

1 reference

1

Susanne Perkhofer

1 reference

16 August 2017

7

Cornelia Lass-Flörl

1 reference

16 August 2017

5

Reinhard Würzner

1 reference

16 August 2017

Manuel Cuenca-Estrella

series ordinal

3

object named as

Manuel Cuenca-Estrella

1 reference

16 August 2017

Maria Locher

2

1 reference

16 August 2017

Reinhard Rüchel

series ordinal

4

1 reference

16 August 2017

Manfred P Dierich

series ordinal

6

1 reference

16 August 2017

language of work or name

English

0 references

publication date

5 May 2008

1 reference

Antimicrobial Agents and Chemotherapy

16 August 2017

1 reference

16 August 2017

52

1 reference

16 August 2017

7

1 reference

16 August 2017

2636-2638

1 reference

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

Toward more effective antifungal therapy: the prospects of combination therapy.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

Activity of posaconazole in treatment of experimental disseminated zygomycosis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

Zygomycetes in human disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

Successful treatment of sinusitis caused by Cunninghamella bertholletiae

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

Synergistic action of amphotericin B and rifampin against Rhizopus species

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

Synergistic effect of posaconazole and caspofungin against clinical zygomycetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

Posaconazole prophylaxis in experimental systemic zygomycosis

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

In vitro studies on the activity of amphotericin B and lipid-based amphotericin B formulations against Aspergillus conidia and hyphae

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

In vitro susceptibilities of zygomycetes to conventional and new antifungals

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443899

Combination antifungal therapy

5 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18458135

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

1 reference

https://pubmed.ncbi.nlm.nih.gov/18458135

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Antifungal susceptibility testing inAspergillusspp. according to EUCAST methodology

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18458135

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.00492-08

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

18458135

1 reference